Skip to main content

Day: September 18, 2025

InterDigital appoints Julia C. Mattis as Chief Licensing Officer

WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video, and AI technology research and development company, today announced that Julia C. Mattis has been appointed as the company’s new Chief Licensing Officer, reporting to Liren Chen, President and Chief Executive Officer of InterDigital. Julia joined InterDigital in 2010 and has worked in several senior positions across the licensing team including Chief Licensing Counsel, Head of Smartphone Licensing, and, most recently, Interim Chief Licensing Officer. “Throughout her time at InterDigital, Julia has been a key part of our licensing success, overseeing many of our largest licenses and helping us to sign agreements worth more than $4 billion in total contract value since 2021,” commented Liren Chen, President and Chief Executive...

Continue reading

Sompo appoints Alessandrea Quane as CEO, International Markets

Sompo appoints Alessandrea Quane as CEO, International MarketsAlessandrea QuanePEMBROKE, Bermuda, Sept. 18, 2025 (GLOBE NEWSWIRE) — Sompo, a leading global provider of commercial and consumer property and casualty (re)insurance, today announced the appointment of Alessandrea (Alessa) Quane as Chief Executive Officer (CEO) International Markets, subject to regulatory approval. Effective immediately and reporting directly to James Shea, CEO, Sompo P&C, Ms Quane will be responsible for managing and overseeing Sompo’s Commercial and Consumer Insurance operations outside of North America and Japan. The regional management of the United Kingdom, Continental Europe (including Turkey), Brazil and Asia Pacific (excluding Japan) will report directly to Ms Quane. Mr Shea said: “I am delighted to welcome Alessa to Sompo. She...

Continue reading

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus dulaglutide1 Data also highlighted Ozempic® was associated with a 26% lower risk of death versus dulaglutide1 This study is the first to directly compare these glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications in everyday real-life use. It fills a significant gap in understanding their effects on heart health in older people at high risk, which could help support informed treatment decisions and health policies.1Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was associated...

Continue reading

Trident Resources Expands Inaugural Drill Program at Contact Lake Gold Project, Saskatchewan

Vancouver, BC, Sept. 18, 2025 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”)  is pleased to announce an expansion of its current inaugural drill exploration program at its 100% owned Contact Lake Project, (“Contact Lake” or the “Project”) located in Saskatchewan. The drill program is focused on confirming historical gold grades and discovering new mineralized zones both adjacent to and below the historical underground mine workings. Trident is very pleased with the drilling progress as well as the visual indications of mineralization thus far, and has elected to increase the program from 5,000m to over 6,500m in 18-20 drill holes. The Company is fully funded for this increase with over C$11M in its treasury. Contact Lake Project Location Map:https://www.tridentresourcescorp.com/projects/contact-lake-gold-project/#&gid=1&pid=1 Drill...

Continue reading

Advantest Expands 7038 System-Level Test Platform with Right-Sized Single Test Rack Solution for High-Volume Manufacturing

New liquid-cooling enabled system delivers affordable, high-density SLT and burn-in test for high-demand, lower-volume HPC, AI, and automotive devices7038 Single Test Rack7038 Single Test Rack (STR) system-level test (SLT) and burn-in test (BI) solution.TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced its 7038 Single Test Rack (STR) system-level test (SLT) and burn-in test (BI) solution. The 7038 STR extends the company’s proven 7038 SLT platform with a lower-cost architecture optimized for slot-based automated test solutions, enabling right-sized SLT deployment in the production of artificial intelligence (AI), high-performance compute (HPC), automotive, and other low- to mid-volume devices. The new 7038 STR delivers liquid-cooled...

Continue reading

AB Akola Group to invest €4.8 million in the expansion of two dairy farms: milk production at Sidabravo and Žibartonių ŽŪB to grow by one-third

AB Akola Group, one of the largest agricultural and food production groups in the Baltic States, is launching dairy farm modernization projects worth more than €4.8 million at its Sidabravo and Žibartonių agricultural companies (ŽUB). Advanced milking equipment and upgraded infrastructure will be installed, and later the herd of milking cows will be increased to achieve significant growth in milk production. “These investments are a strategic step towards increasing the efficiency of our Group’s farms and ensuring competitiveness in the market. This will allow us to increase production volumes, reduce costs, improve working conditions, and ensure higher sustainability standards. In this way, we will create value for both our shareholders and the entire milk supply chain,” says Mažvydas Šileika, CFO and member of the board...

Continue reading

82% of organizations now plan to increase investment in environmental sustainability in the next 12–18 months as a core future-proofing strategy

Press contact:Sereydana OumTel.: +33 6 61 42 03 59E-mail: sereydana.oum@capgemini.com 82% of organizations now plan to increase investment in environmental sustainability in the next 12–18 months as a core future-proofing strategy The majority of organizations have been affected by climate disruption, yet executives are struggling to actively prepare for increased climate risks Paris, September 18, 2025 – The fourth edition of the Capgemini Research Institute’s report, “A world in balance 2025: Unlocking resilience and long-term value through environmental action,” released today, finds that organizations remain committed to sustainability despite global uncertainty. In fact, three quarters of them say it is a core future-proofing strategy for their organizations to drive long-term competitiveness, innovation, and resilience. However,...

Continue reading

Robex Announces Acceleration of Warrant Expiry Date

QUEBEC CITY, Sept. 18, 2025 (GLOBE NEWSWIRE) — West African gold producer and developer Robex Resources Inc. (“Robex” or the “Company”) (ASX: RXR | TSX-V: RBX | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to announce the acceleration of the expiry date set for 27 June 2026 (the “Expiry Date”) relating to its listed common share purchase warrants issued on 27 June 2024 (the “2024 Warrants”). The 2024 Warrants were originally granted in connection with the Company’s equity financing, with each 2024 Warrant entitling the holder to acquire one common share of Robex at an exercise price of C$2.55. Under the terms of the 2024 Warrants, Robex is entitled to accelerate the Expiry Date if the volume weighted average trading price (“VWAP”) and the closing price of the Company’s common shares on the TSX Venture Exchange equals or exceeds...

Continue reading

Biotalys Reports Half-Year 2025 Financial Results and Business Highlights

Press release – regulated information Ghent, Belgium, Sept. 18, 2025 (GLOBE NEWSWIRE) —    Substantial progress in both the U.S. and Europe in the regulatory review of Biotalys’ first candidate biofungicide EVOCA™* Patent protection for EVOCA in Brazil and China, and for a BioFun-6 lead candidate in the U.S. Strategic partnership with AgroFresh to expand into post-harvest segment Leadership team expanded with proven industry executives Cash and cash equivalents amounted to €15.7 million as of the end of June 2025, offering a financial runway into May 2026 Management to host a conference call and live webcast at 15:00 CEST / 14:00 GMT / 09:00 AM ET today, details belowBiotalys (Euronext – BTLS) today announces its key business achievements and consolidated financial results for the first half of 2025, prepared...

Continue reading

89bio, Inc. Announces Agreement to be Acquired by Roche

– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin’s potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Group as part of Roche’s Pharmaceuticals Division – SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has entered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.